authorization for its covenant 19 |
4.16 |
Jump to 4.0 |
|
|
vaccine has 90 efficacy but those trials |
4.8 |
Jump to 8.16 |
|
|
now in a first on cnbc interview is |
3.841 |
Jump to 19.039 |
|
|
two years ago in this process a year and |
4.48 |
Jump to 47.2 |
|
|
basically zero capacity and we've built |
3.84 |
Jump to 51.68 |
|
|
and then the first quarter will be a |
3.519 |
Jump to 103.92 |
|
|
scale where we can produce over 2 |
7.28 |
Jump to 105.6 |
|
|
billion doses in 2022 on a global basis |
5.441 |
Jump to 107.439 |
|
|
well a couple unique features uh one is |
5.36 |
Jump to 145.04 |
|
|
did our phase three efficacy trials |
5.44 |
Jump to 188.879 |
|
|